Detailed mechanistic research is also needed to establish the relative contributions of G protein- and β-arrestin-mediated effects at both GLP-1R and GCGR and will help clarify how investigational incretin receptor agonists are prioritised during drug development for T2D and obesity. Here, GCGR is linked to obesity disorder.